Overview

A Study to Determine the Pharmacokinetics (PK) of Single Intravenous (IV) Dose of Vedolizumab 300 Milligram (mg) in Healthy Adult Chinese Participants

Status:
Completed
Trial end date:
2018-09-05
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the PK of vedolizumab following a single intravenous infusion in healthy adult Chinese participants.
Phase:
Phase 1
Details
Lead Sponsor:
Takeda
Treatments:
Vedolizumab